Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06374797 · ClinicalTrials.gov registry record · Phase 2
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
A Phase 2 study of Acute Kidney Injury, sponsored by CalciMedica.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06374797 is a Phase 2 study of Acute Kidney Injury that is active but no longer recruiting, run by CalciMedica. The registered enrollment target is 150 participants, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06374797, a Phase 2 study of Acute Kidney Injury, is active but no longer recruiting, sponsored by CalciMedica.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Auxora
Study Locations (20)
California
- UCLA - Los Angeles
- Stanford Health Care - Stanford
- Torrance Memorial Medical Center - Torrance
Massachusetts
- Brigham & Woman's Hospital - Boston
- Lahey Hospital and Medical Center - Burlington
Michigan
- Henry Ford - Detroit
- My Michigan Health - Midland
Missouri
- University of Missouri - Columbia
- Hannibal Regional - Hannibal
Alabama
- University of Alabama - Birmingham
Arizona
- Chandler Regional Hospital - Chandler
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06374797
The ClinicalTrials.gov registry entry for NCT06374797 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The listed sponsor is CalciMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06374797 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06374797 about?
NCT06374797 is a clinical study titled "A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"". Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days...
What is the current status of trial NCT06374797?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-07-01. Estimated completion is 2026-04.
What conditions does trial NCT06374797 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06374797?
The interventions under investigation include: Placebo (DRUG), Auxora (DRUG).
Who is sponsoring clinical trial NCT06374797?
This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06374797 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.